Biopharmaceuticals

Cell engineering
#Automation #biological engineering #Biomanufacturing #Biopharmaceuticals #Biosecurity #Cell programming

Ginkgo Bioworks expands its R&D facilities 

Boston-based Ginkgo Bioworks, which is building a platform for cell programming and biosecurity, has launched Bioworks7, the latest expansion of its biological engineering foundry.   With this new space, Ginkgo’s increased capacity will serve partners in cell and gene therapy, biomanufacturing and general mammalian programming for therapeutic applications… Read More

#Business & Investment #News

Virus-like particles
#Biopharmaceuticals #Cell and gene therapy #Collaboration #Gene delivery #Gene therapy #Partnership #Vector BioPharma

Vector and iBET collaborate to accelerate gene delivery platform

Vector BioPharma and the Instituto de Biologia Experimental e Tecnológica (iBET) have agreed a multi-phase collaboration to advance the technical development of Vector’s gene delivery platform.  Vector BioPharma’s gene delivery platform combines high-capacity virus-like particles with exogenous, high-avidity adapter proteins.  Lorenz Mayr, CEO at Vector… Read More

#Business & Investment #News

PrismA ELISA kit
#Assay development optimisation & technology #Biopharmaceuticals #Cytiva #Monoclonal antibodies

New PrismA ELISA kit for impurity testing

This article is sponsored by Cytiva. The new PrismA ELISA kit is an enzyme-linked immunosorbent assay designed to measure residual ligand leakage when using MabSelect PrismA chromatography resin and Fibro PrismA chromatography adsorbers. The kit is used during the development and manufacture of monoclonal antibody (mAb) biopharmaceuticals. … Read More

#News

Acute myeloid leukaemia
#Acute Myeloid Leukaemia #Biopharmaceuticals #Clinical trials #Drug development

Initially positive findings from AML treatment study 

A study by Ellipses Pharma, a global drug development company focused on accelerating the development of new oncology treatments, has presented preliminary data from the first in human Phase I/II trial of EP0042, a dual FLT-3 an Aurora kinase inhibitor, in patients with acute myeloid leukaemia (AML). … Read More

#News

Diabetic macular oedema
#Biopharmaceuticals #Diabetes #Ophthalmology #Phase II trial #Rezolute

Oral therapy for diabetic macular oedema progresses to Phase II

Biopharmaceutical company Rezolute has initiated a Phase II proof-of-concept study for RZ402, a plasma kallikrein inhibitor (PKI) being developed as an oral therapy for the treatment of diabetic macular oedema (DMO).   The current standard of care for DMO is anti-vascular growth factor (anti-VEGF) injections into the eye,… Read More

#News

#AI / data analytics / healthtech / informatics #Biologics / Biotechnology #Biopharmaceuticals #Cell and gene therapy #Diversity #Market reporting #Mergers and acquisitions #Personalised medicine #Pharmaceutical industry #Precision medicine

Drug discovery in 2023: Five key predictions

As 2022 draws to a close, life sciences market analysts attempt to correctly predict what the next 12 months might bring to the drug discovery sector. DDW’s Diana Spencer summarises the key trends likely to impact the market in 2023.  1. There will be greater emphasis on diversity… Read More

#Exclusive Content #Trends & Analysis

Amaranth oil
#Biopharmaceuticals #Drug discovery #Immunology / Virology & Vaccines #Plant-based

Plant-based squalene alternative suitable for vaccine use

Evonik has launched a non-animal-derived squalene suitable for vaccines and other pharmaceutical applications. PhytoSquene is the first known amaranth oil-derived squalene on the market for use in adjuvants in parenteral dosage forms. It is an alternative to animal-derived squalene, which for pharmaceutical applications is typically sourced from shark liver oil. Read More

#News

#Biopharmaceuticals #Cell line development #Cell lines #Picodroplet technology #Single cell sorter #Single-cell analysis

Embedding quality into cell line development through the application of an innovative picodroplet-based single cell sorter

Generation of a highly expressing, regulatory acceptable clonal cell line is the first key activity in the development of a biopharmaceutical. Cell line development is labour intensive, time consuming and costly and is subject to stringent regulations to ensure patient safety. Dr Jonathan H Dempsey All cell lines used to… Read More

Webinar date:
Brought to you by Sphere Fluidics
#Webinars

#Biopharmaceuticals #Drug discovery #Drug targets #Drug technology #Pharmaceuticals #Quantum computing #R&D #Therapeutics

Podcast: Complex problems require complex solutions

This is the latest episode of the free DDW podcast, “Complex problems require complex solutions”. It covers two articles written for Volume 23, Issue 1 – Winter 2021/22 of DDW. They are called “How quantum computing can benefit drug discovery” and “Sitting down with Dr Michael Hayden from… Read More

#News

#Biopharma #Biopharmaceuticals #DNA #Synthetic biology

Why synthetic biology is the next big thing for biopharma 

Listen to this article on the DDW Podcast: ‘Can synthetic biology save us?’ and ‘synthetic biology can benefit us all’, are just some of the headlines this emerging scientific field has recently elicited. Lu Rahman speaks to Dr Emily Leproust, Founder and CEO of Twist Biopharma, about the potential… Read More

#Exclusive Content

#Automation / robotics #Biopharmaceuticals #Cryo-EM #Sample preparation #Webinar

Cryo-EM for understanding potential drug targets

Learn more about the importance of high throughput Cryo-EM on 1 November at 9am PDT, 12pm EDT, 4pm GMT or 5pm CET in this free webinar, hosted by DDW and supported by SPT Labtech. Register for free here. Cryo-EM has been adopted into drug discovery workflows by the pharmaceutical… Read More

#News

#Automation / robotics #Biopharmaceuticals #Cryo-EM #Sample preparation

Cryo-EM and drug discovery workflows: Exclusive webinar

Don’t miss out on this free webinar on 1 November at 9am PDT, 12pm EDT, 4pm GMT, 5pm CET. It is called Utilising novel sample preparation techniques to enhance Cryo-EM structural analysis and is hosted by DDW and supported by SPT Labtech. Confirm your attendance by registering free now. Read More

#News

#AI #Biopharmaceuticals #Collaboration #Neuroscience #Psychiatry #Therapeutics

Collaboration extended in severe neuropsychiatric disorders 

Clinical-stage biopharmaceutical company Karuna Therapeutics has extended its drug discovery collaboration with PsychoGenics, AI-enabled phenotypic drug discovery and preclinical CRO services.  The collaboration aims to identify potential novel drug candidates for the treatment of severe neuropsychiatric disorders.  The initial multi-year agreement, announced in July 2020,… Read More

#News

#Automation / robotics #Biopharmaceuticals #Cryo-EM #Sample preparation

Novel sample preparation techniques enhance Cryo-EM structural analysis

Join DDW on 1 November at 9am PDT, 12pm EDT, 4pm GMT or 5pm CET for this exclusive webinar – Utilising novel sample preparation techniques to enhance Cryo-EM structural analysis. Register free here. Cryo-EM has been adopted into drug discovery workflows by the pharmaceutical and biotechnology industries having proved… Read More

#News

#Biopharmaceuticals #Drug development #eBook #LC-MS

eBook – LC-MS Analysis for (Bio)pharmaceutical Research

This is the seventh eBook of the Hamilton series “LC-MS Analysis for (Bio)pharmaceutical Research”. This ebook covers: The role of LC-MS in the drug development process The drivers behind the need for LC-MS sample prep automation in biopharma The modules and full liquid handling automation solutions that Hamilton offers… Read More

#News

#Biopharmaceuticals #Drug development #Liquid handling #Research

LC-MS Analysis for (Bio)pharmaceutical Research

In the seventh eBook of the Hamilton series “LC-MS Analysis for (Bio)pharmaceutical Research”, we discuss: The role of LC-MS in the drug development process The drivers behind the need for LC-MS sample prep automation in biopharma The modules and full liquid handling automation solutions that Hamilton offers for LC-MS… Read More

#Intelligence #Resources